FRESENIUS SE &/S (OTCMKTS:FSNUY) and Anika Therapeutics (NASDAQ:ANIK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.
This is a summary of recent ratings for FRESENIUS SE &/S and Anika Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|FRESENIUS SE &/S||0||3||1||0||2.25|
Volatility & Risk
FRESENIUS SE &/S has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.
Valuation & Earnings
This table compares FRESENIUS SE &/S and Anika Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|FRESENIUS SE &/S||$38.28 billion||0.80||$2.05 billion||$0.92||15.01|
|Anika Therapeutics||$105.56 million||3.99||$18.72 million||$1.84||16.10|
FRESENIUS SE &/S has higher revenue and earnings than Anika Therapeutics. FRESENIUS SE &/S is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
0.1% of FRESENIUS SE &/S shares are owned by institutional investors. Comparatively, 89.8% of Anika Therapeutics shares are owned by institutional investors. 8.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 1.1%. Anika Therapeutics does not pay a dividend. FRESENIUS SE &/S pays out 16.3% of its earnings in the form of a dividend.
This table compares FRESENIUS SE &/S and Anika Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|FRESENIUS SE &/S||5.91%||12.53%||3.85%|
Anika Therapeutics beats FRESENIUS SE &/S on 12 of the 16 factors compared between the two stocks.
FRESENIUS SE &/S Company Profile
Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.